Dr. Chin Hur, MD

Dr. Hur practices at Trustees of Columbia University in the City of New York in New York, New York.

Dr. Hur's NPI, 1548278526, was assigned on August 4, 2006. Dr. Hur graduated from The Johns Hopkins University School of Medicine in 1995. Dr. Hur holds New York license 294288.

Dr. Hur's primary practice is Trustees of Columbia University in the City of New York, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. Hur's primary practice is Trustees of Columbia University in the City of New York in New York, New York. Dr. Hur is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Hur to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hur practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Hur's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Hur's licenses on file in 2 states: New York and Massachusetts.

Dmand AI lists colonoscopy, gastrointestinal inflammation and upper GI endoscopy among the conditions Dr. Hur treats.

CMS data shows 13 Medicare services from Dr. Hur across 1 procedure code in 2022, all of them office visits, for 25 Medicare patients. Medicare paid $1,159 for them. Every service was in an office.

CMS counts 25 Medicare patients who saw Dr. Hur in 2024. The largest group is 65 to 74, with 11 patients. 75% of them have high cholesterol, and 72% have high blood pressure. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hur's median patient age at 68, with 60% women.

In 2024, Dr. Hur wrote 105 Medicare Part D claims for 52 patients. 89% of them were for generic drugs. CMS names the drug for 66 of them, across 5 drugs with 11 or more claims each, at $977 in total drug cost. In 2023, CMS named 43 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Hur for performance year 2024, reported through an alternative payment model (APM). Dr. Hur accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hur as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 254 papers to Dr. Hur, published from 2004 to 2025. 2021 was the busiest year, with 28. The most frequent topics are Cost-Benefit Analysis, Adenocarcinoma and Esophageal Neoplasms. Dr. Hur has published most often in Clin Gastroenterol Hepatol. Dr. Hur's most frequent co-authors are Jason D. Wright, MD, Monika Laszkowska, MD and Sheila D. Rustgi.

Dmand AI links Dr. Hur to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Gastrointestinal Hemorrhage, Heartburn and Rectal Diseases.

CMS Open Payments shows 9 general payments to Dr. Hur from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 96% of the total. Novo Nordisk AS paid the most, $66,960.

Dr. Hur graduated from The Johns Hopkins University School of Medicine in 1995. Dr. Hur is a member of ACG and AGA.

Dr. Hur is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.